Cognitive impairment associated with schizophrenia: A review of the humanistic burden

Advances in Therapy

Volumn 29, Issue 2, 2012, Pages 148-162

  Kitchen, Helen ^a   Rofail, Diana ^a   Heron, Louise ^a   Sacco, Pat ^b  

^a ADELPHI REAL WORLD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

burden; cognitive impairment associated with schizophrenia; conceptual model; cost; humanistic; patient reported outcome; schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; COST OF ILLNESS; DAILY LIFE ACTIVITY; DATA BASE; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMANISM; LEARNING DISORDER; MEMORY DISORDER; PATIENT; PATIENT COMPLIANCE; PROBLEM SOLVING; PROCESSING SPEED; PRODUCTIVITY; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; REVIEW; SCHIZOPHRENIA; SELF REPORT; SOCIAL COGNITION; SYMPTOM; WORK;

ACTIVITIES OF DAILY LIVING; COGNITION DISORDERS; COST OF ILLNESS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84857900236     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0001-4     Document Type: Review

References (81)

1. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85-94. (Pubitemid 23059313)
2. WHO. Mental Health and Substance Abuse: Facts and Figures, Schizophrenia. Available at: http://www.searo.who.int/en/section1174/section1199/section1567- 6744.htm. Accessed November 1, 2009.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 2011.
4. Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64:524-531. (Pubitemid 36618280)
5. Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34:369-374. (Pubitemid 38239645)
6. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am. 2003;26:25-40. (Pubitemid 36384346)
7. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry. 1999;60(suppl. 3):3-7;discussion 8.
8. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122-1129. (Pubitemid 41442278)
9. Bowie C, Harvey P. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2:531-536. (Pubitemid 46321882)
10. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1-21. (Pubitemid 32193047)
11. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437-446. (Pubitemid 27294667)
12. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry. 2008;7:22-28. (Pubitemid 351338182)
13. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559. (Pubitemid 30191193)
14. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101-113. (Pubitemid 38041108)
15. Merlotti E, Piegari G, Galderisi S. Cognitive impairment as a core feature of schizophrenia. Minerva Psichiatr. 2005;46:67-77. (Pubitemid 40979444)
16. Meltzer HY. Beyond control of acute exacerbation: enhancing affective and cognitive outcomes. CNS Spectr. 2003;8(suppl. 2):16-8, 22.
17. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65:361-372.
18. Ginsberg D, Schooler N, Buckley P, Harvey P, Weiden P. Optimizing treatment of schizophrenia. CNS Spectr. 2005;10:1-3.
19. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004;72:1-3. (Pubitemid 39452899)
20. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115-1122. (Pubitemid 47529336)
21. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647. (Pubitemid 46878665)
22. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19. (Pubitemid 41214353)
23. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull. 1999;25:309-319. (Pubitemid 29272507)
24. Nuechterlein K, Green M, Kern R, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213. (Pubitemid 351704520)
25. McCabe R, Saidi M, Priebe S. Patient-reported outcomes in schizophrenia. Br J Psychiatry. 2007;50:S21-S28. (Pubitemid 47204551)
26. Hunter R, Cameron R, Norrie J. Using patient-reported outcomes in schizophrenia: the Scottish Schizophrenia Outcomes Study. Psychiatr Serv. 2009;60:240-245.
27. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51. (Pubitemid 39452904)
28. McGrath C, Rofail D, Gargon E, Abetz L. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease. Health Qual Life Outcomes. 2010;8:23.
29. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853-859.
30. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72:5-9. (Pubitemid 39452900)
31. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Health Qual Life Outcomes. 2006;4:79.
32. University of York. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care [Internet]. York: University of York; 2009. 27-11-2009. Available at: http://www.york.ac.uk/inst/ crd/index-guidance.htm. Accessed November 20, 2009.
33. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307. (Pubitemid 39164514)
34. Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol. 2006;20(suppl.):6-19. (Pubitemid 44583374)
35. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: A content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102-111.
36. Sharma T. Atypical antipsychotics and cognition in schizophrenia. Arch Gen Psychiatry. 2002;59:571-572.
37. Sharma T. Impact on cognition of the use of antipsychotics. Curr Med Res Opin. 2002;18(suppl. 3):S13-S17.
38. Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol. 2006;16(suppl. 3):S156-S162. (Pubitemid 44175820)
39. Harvey P, Patterson T, Potter L, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163:1918-1925. (Pubitemid 44807783)
40. Wittorf A, Wiedemann G, Buchkremer G, Klingberg S. Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. Eur Arch Psychiatry Clin Neurosci. 2007;258:48-58. (Pubitemid 351208249)
41. Heinrichs R. Cognitive improvement in response to antipsychotic drugs: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:631-632. (Pubitemid 46878664)
42. Hofer A, Baumgartner S, Bodner T, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry. 2005;20:395-402. (Pubitemid 41318005)
43. Chue P. The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol. 2006;20(suppl.):38-56. (Pubitemid 44583376)
44. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932-939.
45. Kasper S. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. Eur Neuropsychopharmacol. 2006;16(suppl. 3):S135-S141. Epub: 2006.
46. Stratta P, Donda P, Rossi A, Rossi A. Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. Hum Psychopharmacol. 2005;20:401-408. (Pubitemid 41269697)
47. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57:201-208.
48. Ciudad A, Olivares J, Bousono M, Gomez J, Alvarez E. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1515-1522. (Pubitemid 44634947)
49. Bell M, Mishara A. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr Res. 2006;81:17-27. (Pubitemid 41817203)
50. O'Grada C, Dinan T. Executive function in schizophrenia: what impact do antipsychotics have? Hum Psychopharmacol. 2007;22:397-406. (Pubitemid 47316124)
51. Meltzer HY. Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr. 2004;9(suppl. 11):15-24. (Pubitemid 39473435)
52. Carpenter J. Clinical constructs and therapeutic discovery. Schizophr Res. 2004;72:69-73. (Pubitemid 39452906)
53. Delle CR, Salviati M, Fiorentini S, Biondi M. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol. 2007;15:563-568. (Pubitemid 351163131)
54. Gráda C, Barry S, McGlade N, et al. Does the ability to sustain attention underlie symptom severity in schizophrenia? Schizophr Res. 2009;107:319-323.
55. Harris JG, Minassian A, Perry W. Stability of attention deficits in schizophrenia. Schizophr Res. 2007;91:107-111. (Pubitemid 46335852)
56. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol. 2002;25:272-275. (Pubitemid 35239487)
57. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:280-287.
58. Laes J, Sponheim S. Does cognition predict community function only in schizophrenia?: a study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr Res. 2006;84:121-131.
59. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14:87-92. (Pubitemid 38175425)
60. Guaiana G, Tyson P, Roberts K, Mortimer A. Negative symptoms and not cognition predict social functioning among patients with schizophrenia. Schweiz Arch Neurol Psychiatr. 2007;158:25-31. (Pubitemid 46524166)
61. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl). 2002;162:11-17. (Pubitemid 34639550)
62. Goff D. New insights into clinical response in schizophrenia: From dopamine Dsub 2 receptor occupancy to patients' quality of life. Am J Psychiatry. 2008;165:940-943.
63. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry. 1999;60(suppl. 23):25-28.
64. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry. 2003;64:33-39.
65. Perlick DA, Rosenheck RA, Kaczynski R, Bingham S, Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res. 2008;99:192-199. (Pubitemid 351249111)
66. Mohamed S, Rosenheck R, Swartz M, et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry. 2008;165:978-987.
67. Lipkovich IA, Deberdt W, Csernansky JG, et al. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry. 2009;9:44.
68. Percudani M. Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Acta Psychiatr Scand. 1999;99:271-280.
69. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:23-41. (Pubitemid 46613421)
70. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21:2017-2028. (Pubitemid 41803113)
71. Patel A, Everitt B, Knapp M, et al. Schizophrenia patients with cognitive deficits: factors associated with costs. Schizophr Bull. 2006;32:776-785. (Pubitemid 44412865)
72. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Mental Health Policy Econ. 2003;6:67-75. (Pubitemid 37304742)
73. McCombs JS, Nichol MB, Johnstone BM, et al. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv. 2000;51:525-527. (Pubitemid 30212098)
74. Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy. 2000;51:1-18. (Pubitemid 30089755)
75. Dernovsek MZ, Prevolnik R, Rebolj M, Tavcar R. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry. 2001;16:474-482. (Pubitemid 34042129)
76. Heider D, Bernert S, Konig H, et al. Direct medical mental healthcare costs of schizophrenia in France, German and the United Kingdom: findings from the European Schizophrenia Cohort. Eur Psychiatry. 2009;24:216-224.
77. Rofail D, Heelis R, Gournay K. Results of a thematic analysis to explore the experiences of patients with schizophrenia taking antipsychotic medication. Clin Ther. 2009;31 (Pt 1):1488-1496.
78. Knapp M, Razzouk D. Costs of schizophrenia. Psychiatry. 2008;7:491-494.
79. Percudani M, Barbui C, Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: An economic perspective. Pharmacoeconomics. 2004;22:701-718. (Pubitemid 38998496)
80. Rosenheck R, Leslie D, Keefe R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163:411-417. (Pubitemid 44469382)
81. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42-46. (Pubitemid 30450663)